Preparation of carbon nanotube doped fenbufen molecularly imprinted polymer sustained-release material

A molecular imprinting and carbon nanotube technology, which can be used in medical preparations without active ingredients, medical preparations containing active ingredients, drug combinations, etc., and can solve problems such as poor dispersion and difficulty in carbon nanotube composites.

Active Publication Date: 2017-06-20
TIANJIN MEDICAL UNIV
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its poor dispersibility in solvents makes it difficu

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation of carbon nanotube doped fenbufen molecularly imprinted polymer sustained-release material
  • Preparation of carbon nanotube doped fenbufen molecularly imprinted polymer sustained-release material
  • Preparation of carbon nanotube doped fenbufen molecularly imprinted polymer sustained-release material

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] In order to obtain the best synthesis formula of fenbufen carbon nanotube doped controlled-release molecularly imprinted polymer, we optimized the synthesis formula of fenbufen imprinted monolithic column, the specific operation steps are as follows:

[0032] Preparation method of fenbufen molecularly imprinted monolithic column doped with single-walled carbon nanotubes using ionic liquid and deep eutectic solvent as binary porogen:

[0033] a. Mix 0.75% of the template molecule fenbufen (both in mass percentages), 0.29% of the initiator azobisisobutyronitrile, and 0.06% of single-walled carbon nanotubes, and add a mass fraction of 54.03% [BMIM]BF 4Dissolve and mix with mass fraction 21.76% ChCl (choline chloride) / EG (ethylene glycol) at room temperature by ultrasonic (40KHz, 10min), then add mass fraction 2.71% 4-vinylpyridine and mass fraction 20.40% Ethylene glycol methacrylate continues to be ultrasonically mixed to remove the oxygen in the mixed reaction liquid, in...

Embodiment 2

[0041] Drug Release Experiments A model to study the kinetics of drug release from fenbufen molecularly imprinted polymers. In order to investigate the drug release model, the total amount of drug released by fenbufen molecularly imprinted polymers and non-imprinted polymers within a certain period of time was determined. The specific operation steps are as follows:

[0042] a. Mix template molecule fenbufen 0.75% (both mass percentages), initiator azobisisobutyronitrile 0.29%, single-walled carbon nanotubes 0.06%, add mass fraction 54.03% [BMIM]BF 4 With the mass fraction of 21.76% ChCl / EG (mol / mol, 1:3), ultrasonically dissolve and mix at room temperature, and then add the mass fraction of 2.71% 4-vinylpyridine and the mass fraction of 20.40% ethylene glycol dimethacrylate Continue to sonicate to make it evenly mixed, remove the oxygen in the mixed reaction solution, seal it, and react in a water bath at 60°C for 14 h;

[0043] b. The molecularly imprinted polymer obtained...

Embodiment 3

[0049] Pharmacokinetic experiments to study the blood concentration of fenbufen molecularly imprinted polymer in rats over time. In order to investigate the controlled-release effect of the drug in rats, the blood drug concentration in rats was determined within a certain period of time after oral administration of different types of fenbufen carrier materials.

[0050] The specific operation steps are as follows:

[0051] a. Synthesize molecularly imprinted polymers containing carbon nanotubes, molecularly imprinted polymers without carbon nanotubes, and non-imprinted polymers containing carbon nanotubes by the same method as above (Example 2).

[0052] b. Fenbufen Tablets (Zhejiang Weikang Pharmaceutical Co., Ltd.), a commercial drug in the control group, was purchased from Tianjin Laomin Pharmacy Chain Co., Ltd.; single-walled carbon nanotubes were purchased from Nanjing Xianfeng Nano Technology Co., Ltd.

[0053] c. Soak the above prepared material in the acetonitrile sol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to preparation of a carbon nanotube doped fenbufen molecularly imprinted polymer sustained-release material and specifically relates to a fenbufen sustained-release molecularly imprinted polymer material which is prepared by utilizing ionic liquid 1-butyl-3-methylimidazole tetrafluoroborate and a deep-eutectic solvent as a binary pore-foaming agent and doping single-wall carbon nanotubes. The fenbufen sustained-release molecularly imprinted polymer material is prepared from raw materials by mass: 0.67 to 0.76% of fenbufen, 0.03 to 0.06% of single-wall carbon nanotube, 2.41 to 2.75% of 4-vinyl pyridine, 18.16 to 20.69% of ethylene glycol dimethacrylate, 18.37 to 48.39% of deep-eutectic solvent, 30.06 to 57.08% of 1-butyl-3-methylimidazole tetrafluoroborate and 0.25 to 0.29% of azodiisobutyronitrile. The fenbufen sustained-release molecularly imprinted polymer material disclosed by the invention has a good sustained-release effect; in-vivo pharmacokinetics show that compared with 1.5h peak time and 46.1% bioavailability of an imprinted polymer without carbon nanotubes, peak time of blood drug concentration in a rat body can reach 4 hours and bioavailability can be 140% compared with commodity medicine, and performance is stable. The preparation of the carbon nanotube doped fenbufen molecularly imprinted polymer sustained-release material disclosed by the invention lays a foundation for a molecularly imprinted technology to be applied to a medicine transfer system.

Description

technical field [0001] The invention relates to the preparation of a carbon nanotube-doped fenbufen molecularly imprinted polymer controlled and sustained-release material, specifically the ionic liquid 1-butyl-3-methylimidazolium tetrafluoroborate (1-Butyl-3 -methylimidazolium terafluoroborate, [BMIM]BF 4 ) and deep eutectic solvents (deep eutectic solvents, DESs) as binary porogens, doped single-walled carbon nanotubes (single-walled CNTs, SWCNTs) prepared carbon nanotube-doped fenbufen molecularly imprinted polymer control Sustained-release material, pharmacokinetics in vivo shows that compared with the 1.5h peak time and 46.1% bioavailability of non-carbon nanotube imprinted polymers, its plasma drug concentration in rats can reach 4 hours. Hours, the bioavailability is as high as 140% relative to commercial drugs. Background technique [0002] Fenbufen (Fenbufen, FB), chemical name: 1,1'-biphenyl-γ-oxobutanoic acid, it is a new non-steroidal anti-inflammatory and anal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/00A61K47/04A61K47/32A61K31/192A61P29/00
CPCA61K9/0002A61K31/192A61K47/02A61K47/32
Inventor 黄艳萍姚鸿飞刘照胜杨芳芳
Owner TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap